United Therapeutics Corporation (UTHR)

195.10
NASDAQ
Prev Close 200.47
Day Low/High 194.52 / 200.05
52 Wk Low/High 98.37 / 216.90
Exchange NASDAQ
Shares Outstanding 44.89B
Market Cap 9.00B
P/E Ratio 15.87
Div & Yield N.A. (N.A)
United Therapeutics Gets a Second Wind

United Therapeutics Gets a Second Wind

UTHR and many other companies in this space are showing good strength; here's what the charts tell us.

Best Buys for 2021? Look at Small-Cap Biotechs

Best Buys for 2021? Look at Small-Cap Biotechs

Eight favorite stock ideas in the small-cap biotech space.

5 Bearish Bets: Why Pepsi, Cray and 3 Other Stocks Look Good Short

5 Bearish Bets: Why Pepsi, Cray and 3 Other Stocks Look Good Short

Pepsi looks challenged and Cray's chart is 'cray cray.'

United Therapeutics Gets a Quantitative Upgrade

United Therapeutics Gets a Quantitative Upgrade

Shares look to break out from long basing pattern.

United Therapeutics Has Room to Fall Farther

United Therapeutics Has Room to Fall Farther

With the weekly close under the $120 support level, the next chart support lies around $90 -- the lows of 2014.

Why I'm Looking at Biotechs, Not Airlines

Cutthroat competition is good for customers, but not shareholders.

Jump on a Short Squeeze

Jump on a Short Squeeze

These four stocks are all great candidates for this strategy.

Hunting for Straddle Plays

Hunting for Straddle Plays

Low volatility ahead of a long weekend creates good conditions.

Pluristem CEO Seeing the Future in 3D Cells

Pluristem CEO Seeing the Future in 3D Cells

Pluristem's successful stem cell trial last week on muscle injuries is an important first step for the company, says the company's CEO Zami Aberman.

Rules of the Game: Biotechs in Rally Mode

Rules of the Game: Biotechs in Rally Mode

Here are two quality names in the sector to watch for a pullback.

A Famed Investor's Small-Cap Picks

Here are some less-followed names in Joel Greenblatt's portfolio.

The Next Big Thing In Biotech: Decision Week

The Next Big Thing In Biotech: Decision Week

Ziopharm, AP Pharma and Biogen Idec will headline a very big week of approval decisions, Adam Feuerstein, Sr. Columnist at TheStreet, tells Gregg Greenberg.

United Therapeutics downgraded at BMO

Joel Greenblatt's Top 'Magic Formula' Stocks

These three holdings offer consistent earnings growth and impressive returns on invested capital.

Seek Safety in Two Health Care Stocks

Seek Safety in Two Health Care Stocks

United Therapeutics and PharMerica have strong insider buying and should perform in a turbulent market.